Biotech entity
Every one of those 1 sits in a single category, funding. Kailera Therapeutics is most often covered alongside Ben Zercher, which appears in 1 of these 1 story. Kailera Therapeutics appears in 1 tracked Biotech story from July 14, 2026.
Last mentioned: Jul 14, 2026
Entity pulse
Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, funding. Kailera Therapeutics is most often covered alongside Ben Zercher, which appears in 1 of these 1 story. Kailera Therapeutics appears in 1 tracked Biotech story from July 14, 2026. The tracked stories average 2 original sources each.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 1 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Kailera Therapeutics. Shared-story counts are live from our verified record — not editorial picks.
Biotech venture capital surged to $9.1 billion in the first half of 2026, yet the majority flowed to companies with drugs already in clinical testing, leaving preclinical-stage firms facing a severe funding drought. This divergence threatens the future drug pipeline even as IPO and M&A markets boom.
Source: Gwendolyn Wu · BioPharma Dive
Kailera Therapeutics is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
